IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.

Rxbio, Inc., Johnson City TN

Investigators

Abstract

This contract supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated morbidities and mortalities.